Alector (ALEC) to Release Earnings on Wednesday

Alector (NASDAQ:ALEC) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Alector Stock Performance

ALEC opened at $1.97 on Wednesday. The company has a current ratio of 3.76, a quick ratio of 3.76 and a debt-to-equity ratio of 0.17. Alector has a 1-year low of $0.87 and a 1-year high of $3.40. The company has a market cap of $215.03 million, a price-to-earnings ratio of -1.84 and a beta of 0.64. The company’s fifty day moving average price is $1.72 and its two-hundred day moving average price is $2.01.

Wall Street Analyst Weigh In

Several analysts have recently commented on ALEC shares. Mizuho set a $1.50 price objective on Alector and gave the stock a “neutral” rating in a research note on Wednesday, October 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Alector in a research report on Wednesday, January 21st. HC Wainwright dropped their target price on Alector from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, October 22nd. BTIG Research upgraded Alector from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Finally, Morgan Stanley reissued an “underweight” rating on shares of Alector in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Alector has a consensus rating of “Hold” and an average target price of $3.25.

Insider Transactions at Alector

In other Alector news, CFO Neil Lindsay Berkley sold 37,261 shares of Alector stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $1.12, for a total value of $41,732.32. Following the sale, the chief financial officer owned 374,309 shares of the company’s stock, valued at $419,226.08. The trade was a 9.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Sara Kenkare-Mitra sold 41,687 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total transaction of $46,689.44. Following the sale, the insider owned 501,652 shares in the company, valued at $561,850.24. This represents a 7.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 196,104 shares of company stock valued at $220,064 over the last three months. Corporate insiders own 9.70% of the company’s stock.

Institutional Trading of Alector

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALEC. Prudential Financial Inc. purchased a new stake in Alector in the second quarter worth $30,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Alector during the fourth quarter worth $40,000. XTX Topco Ltd raised its stake in Alector by 125.2% in the second quarter. XTX Topco Ltd now owns 73,338 shares of the company’s stock valued at $103,000 after buying an additional 40,767 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in Alector in the 4th quarter worth approximately $121,000. Finally, Strs Ohio acquired a new stake in Alector during the 1st quarter worth about $126,000. 85.83% of the stock is owned by hedge funds and other institutional investors.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.